Last reviewed · How we verify
Intravesical Onabotulinum Toxin A Injection
At a glance
| Generic name | Intravesical Onabotulinum Toxin A Injection |
|---|---|
| Sponsor | Bagcilar Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections (PHASE4)
- Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections (PHASE4)
- The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder (PHASE3)
- Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: